Literature DB >> 9669274

Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.

S F Nagueh1, N M Lakkis, Z X He, K J Middleton, D Killip, W A Zoghbi, M A Quiñones, R Roberts, M S Verani, N S Kleiman, W H Spencer.   

Abstract

OBJECTIVES: This study was undertaken to evaluate the ability of myocardial contrast echocardiography (MCE) to guide the targeted delivery of ethanol during nonsurgical septal reduction therapy (NSRT) and to assess the relation between the MCE risk area and infarct size determined by enzymatic and radionuclide methods.
BACKGROUND: NSRT with intracoronary ethanol is a new promising treatment for patients with hypertrophic obstructive cardiomyopathy (HOCM). Proper localization and quantification of the septal infarct before ethanol injection are highly desirable. MCE can provide accurate delineation of the vascular territory of the coronary arteries.
METHODS: Twenty-nine patients with HOCM and maximal medical therapy underwent NSRT. The left ventricular outflow tract (LVOT) gradient by Doppler echocardiography at baseline was 53 +/- 16 mm Hg (mean +/- SD). Before NSRT, MCE was performed in all patients with intracoronary sonicated albumin (Albunex). Diluted sonicated albumin (Albunex) was selectively injected into the septal perforator arteries during simultaneous transthoracic imaging. Immediately after MCE, ethanol was injected into the same vessel. Plasma total creatine kinase (CK), total CK-MB fraction and CK-MB fraction subforms were measured at baseline and serially for 36 h.
RESULTS: LVOT gradient decreased to 12 +/- 6 mm Hg (p < 0.001) after NSRT. Accurate mapping of the vascular beds of the septal perforators was successfully attained in all patients by MCE. Furthermore, the MCE risk area correlated well with peak CK (r = 0.79, p < 0.001). Six weeks after NSRT, 23 patients underwent myocardial perfusion studies performed with single-photon emission computed tomography (SPECT). Mean SPECT septal perfusion defect size involved 9.5 +/- 6% of the left ventricle and correlated well with MCE area (r = 0.7), with no statistically significant difference between the risk area estimated by MCE and that by SPECT.
CONCLUSIONS: Estimation of the size of the septal vascular territory with MCE is accurate, safe and feasible in essentially all patients during NSRT. MCE can delineate the perfusion bed of the septal perforators and can predict the infarct size that follows ethanol injection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669274     DOI: 10.1016/s0735-1097(98)00220-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Left ventricular opacification during selective intracoronary injection of echocardiographic contrast in patients with hypertrophic cardiomyopathy.

Authors:  P M Elliott; S J Brecker; W J McKenna
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 2.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

3.  Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation.

Authors:  Felix Y j Keng; Su Min Chang; Eduardo Cwajg; Zuo-Xiang He; Nasser M Lakkis; Sherif F Nagueh; William H Spencer; Mario S Verani
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

4.  Symptomatic hypertrophic obstructive cardiomyopathy: semi-supine bicycle ergometry as a useful provocative manoeuvre to elicit latent gradient.

Authors:  Sanjay Kumar Dhar; Vatchsala Varadharajan; Abdallah Al-Mohammad; Julie Sandoval; Ever D Grech
Journal:  BMJ Case Rep       Date:  2009-03-31

5.  Percutaneous septal ablation: a new treatment for hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss
Journal:  Neth Heart J       Date:  2001-11       Impact factor: 2.380

6.  Cardiac MRI detected septal and lateral myocardial infarction by alcohol septal ablation through the intermediate artery.

Authors:  Mike Saji; Itaru Takamisawa; Nobuo Iguchi; Morimasa Takayama
Journal:  Heart Vessels       Date:  2013-01-11       Impact factor: 2.037

Review 7.  Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment.

Authors:  Maria-Angela Losi; Stefano Nistri; Maurizio Galderisi; Sandro Betocchi; Franco Cecchi; Iacopo Olivotto; Eustachio Agricola; Piercarlo Ballo; Simona Buralli; Antonello D'Andrea; Arcangelo D'Errico; Donato Mele; Susanna Sciomer; Sergio Mondillo
Journal:  Cardiovasc Ultrasound       Date:  2010-03-17       Impact factor: 2.062

8.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; A Rigopoulos; D Welge; P Ziemssen; L Faber
Journal:  Clin Res Cardiol       Date:  2007-09-27       Impact factor: 5.460

9.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04

Review 10.  Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy.

Authors:  Alyson Kelley-Hedgepeth; Martin S Maron
Journal:  Curr Heart Fail Rep       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.